Incyte (INCY)

• Market cap: $14B
• 1 day: 1.02%
• 5 days: 2.07%
• 1 month: -1.85%
• 3 months: 2.44%
• 6 months: 12.41%
• Year to date: 3.71%
• 1 year: 19.53%
• 5 years: -10.85%
• 10 years: -13.55%
• Sector: Industrials
• Industry: Commercial Physical & Biological Research

About: Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Employees: 2,617

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

120% more first-time investments, than exits

New positions opened: 119 | Existing positions closed: 54

102% more call options, than puts

Call options by funds: $68.6M | Put options by funds: $34M

14% more funds holding in top 10

Funds holding in top 10: 7 [Q3] → 8 (+1) [Q4]

14% more repeat investments, than reductions

Existing positions increased: 231 | Existing positions reduced: 203

7% more funds holding

Funds holding: 576 [Q3] → 617 (+41) [Q4]

5% more capital invested

Capital invested by funds: $12B [Q3] → $12.5B (+$586M) [Q4]

0.55% less ownership

Funds ownership: 94.83% [Q3] → 94.29% (-0.55%) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $68 6% downside
• Avg. target: $75 4% upside
• High target: $88 22% upside

6 analyst ratings

• positive: 1 17%
• neutral: 5 83%
• negative: 0 0%

RBC Capital Brian Abrahams 16% 1-year accuracy 13 / 79 met price target	6% downside $68	Sector Perform Maintained	11 Feb 2025
Citigroup David Lebowitz 63% 1-year accuracy 15 / 24 met price target	22% upside $88	Buy Maintained	11 Feb 2025
Stifel Stephen Willey 56% 1-year accuracy 10 / 18 met price target	7% upside $77	Hold Maintained	10 Feb 2025
RBC Capital Leonid Timashev 39% 1-year accuracy 17 / 44 met price target	3% downside $70	Sector Perform Reiterated	23 Jan 2025
Wells Fargo Derek Archila 49% 1-year accuracy 17 / 35 met price target	3% downside $70	Equal-Weight Maintained	19 Dec 2024